Global High Content Screening Market, By Product Type (Cell Imaging and Analysis Equipment, Consumables, HCS Software, HCS Services), By Application (Primary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others), By End User (Pharmaceutical Organizations, Biotechnology Organizations, Research Institutes, Independent CRO, Government Organizations, Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2030 is at US$ 1,847.2 million in 2023 and is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030) by Coherent Market Insights.
A need to control cost in pharmaceutical research and discovery is driving the growth of the High Content Screening market. This is because HCS focuses on improvement of in vitro techniques during safety and toxicity studies to reduce cost, labor and time. For instance, in 2020, PubMed- a free search engine accessing primarily the database of references and abstracts on life sciences and biomedical topics. published an article, according to which the average cost of developing a new drug will rise upto US$ 2.8 billion in 2023. Thus, the digitalization of the current clinical trials is needed to improve trial efficiency, enhance scientific rigor, and expand health equity
Global High Content Screening Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a moderate impact on the Global High Content Screening Market. It boosted R&D after the lifting of lockdowns on one hand white delaying clinical trials of existing vaccines on the other. Developing novel HCS assays acting simultaneously against multiple targets in the SARS-CoV-2 life cycle benefitted anti-COVID-19 drug discovery. According to an article in Pubmed in 2022, multiple studies and reports demonstrate that routine mammograms for breast cancer screening, colonoscopies and other stool-based tests for colorectal cancer screening, Pap or HPV tests for cervical cancer screening, low-dose computerized tomography for lung cancer screening, as well as diagnostic biopsies and surgical procedures had been delayed or not performed since the pandemic.
Global High Content Screening Market: Key Developments
On November 30 , 2022, Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art lab and office facilities.
Browse 38 Market Data Tables and 36 Figures spread through 167 Pages and in-depth TOC on “Global High Content Screening Market”- Forecast to 2030, High Content Screening Market, By Product Type (Cell Imaging and Analysis Equipment, Consumables, HCS Software, HCS Services), By Application (Primary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others), By End User (Pharmaceutical Organizations, Biotechnology Organizations, Research Institutes, Independent CRO, Government Organizations, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/high-content-screening-market-3487
Key Takeaways of the Global High Content Screening Market:
- Global high content screening market to Surpass US$ 1,847.2 million in 2023 with CAGR of 5.8% during the forecast period (2023-2030). The need to find drug treartments after the COVID-19 era, a surge in R&D costs and prevalence of diseases are driving this market growth.
- Among application type, the primary screening segment is estimated to fastest growing in the Global High Content Screening Market over the forecast period. This is because primary screening is the basic separation and isolation technique of micro-organisms in any R&D activity. For instance according to an article published in PubMed, in June 2022, High-throughput in vitro absorption, distribution, metabolism, and excretion (HT-ADME) screening has become a key component of any synthetic molecule drug development endeavour. The range of HT-ADME assays continues to grow in developing areas such as as drug-transporter interactions, early soft spot detection, and ADME screening of peptide drug candidates. Furthermore, because to the massive and high-quality HT-ADME data sets accessible in many biopharma companies, in silico prediction of ADME features using machine learning has gained significant traction in recent years.
- Major players operating in the global high content screening market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., GE HealthCare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher, Yokogawa Electric Corporation, Sysmex Corporation, and Thorlabs, Inc.
